KYMR

26.36

4.46% 1.125

Handel nachbörslich: 26.06 -0.30 -1.14%

Kymera Therapeutics Inc (KYMR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$25.23

Offen:

$24.81

24-Stunden-Volumen:

717.13K

Relative Volume:

1.26

Marktkapitalisierung:

$1.64B

Einnahmen:

$87.56M

Nettoeinkommen (Verlust:

$-167.47M

KGV:

-11.26

EPS:

-2.34

Netto-Cashflow:

$-148.20M

1W Leistung:

-13.26%

1M Leistung:

-15.92%

6M Leistung:

-41.42%

1J Leistung:

-29.97%

1-Tages-Spanne:

$24.43

$26.79

1-Wochen-Bereich:

$24.36

$30.89

52-Wochen-Spanne:

$24.36

$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Firmenname

Kymera Therapeutics Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (676)

Telefon

857-285-5314

Adresse

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

KYMR's Discussions on Twitter

Vergleichen Sie KYMR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KYMR Kymera Therapeutics Inc	26.36	1.64B	87.56M	-167.47M	-148.20M	-2.34
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-13	Eingeleitet	Citigroup	Buy
2024-12-10	Eingeleitet	BTIG Research	Buy
2024-12-06	Eingeleitet	BMO Capital Markets	Market Perform
2024-12-02	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-11-18	Eingeleitet	Stephens	Overweight
2024-09-09	Fortgesetzt	Leerink Partners	Outperform
2024-08-26	Hochstufung	Wolfe Research	Peer Perform → Outperform
2024-04-22	Eingeleitet	Oppenheimer	Outperform
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2024-01-04	Hochstufung	JP Morgan	Neutral → Overweight
2024-01-03	Herabstufung	BofA Securities	Buy → Neutral
2023-12-19	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-06-30	Eingeleitet	Truist	Buy
2023-05-05	Hochstufung	Raymond James	Mkt Perform → Outperform
2022-12-06	Herabstufung	Credit Suisse	Outperform → Neutral
2022-11-08	Eingeleitet	Raymond James	Mkt Perform
2022-08-15	Eingeleitet	Jefferies	Buy
2022-08-03	Eingeleitet	Goldman	Buy
2022-07-20	Eingeleitet	SVB Leerink	Mkt Perform
2022-04-28	Eingeleitet	Credit Suisse	Outperform
2022-03-10	Eingeleitet	JP Morgan	Neutral
2022-02-10	Eingeleitet	Wells Fargo	Overweight
2021-09-30	Eingeleitet	B. Riley Securities	Neutral
2021-09-30	Eingeleitet	Stifel	Buy
2021-09-10	Herabstufung	BofA Securities	Buy → Neutral
2021-05-21	Eingeleitet	UBS	Buy
2021-04-14	Eingeleitet	Berenberg	Buy
2020-12-04	Eingeleitet	H.C. Wainwright	Buy
2020-09-15	Eingeleitet	BofA Securities	Neutral
2020-09-15	Eingeleitet	Cowen	Outperform
2020-09-15	Eingeleitet	Guggenheim	Buy
2020-09-15	Eingeleitet	Morgan Stanley	Equal-Weight

Alle ansehen

Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten

Apr 01, 2025

(KYMR) Trading Report - news.stocktradersdaily.com

Apr 01, 2025

Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 01, 2025

Mar 31, 2025

Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia

Mar 31, 2025

Mar 27, 2025

Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 27, 2025

Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada

Mar 27, 2025

Mar 21, 2025

Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 21, 2025

Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 21, 2025

Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 21, 2025

Mar 18, 2025

Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 18, 2025

Mar 15, 2025

Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 15, 2025

Mar 14, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Mar 14, 2025

Mar 13, 2025

Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq

Mar 13, 2025

Mar 11, 2025

(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 11, 2025

Mar 07, 2025

Why Kymera Therapeutics’ Stock is Making Waves - TipRanks

Mar 07, 2025

Mar 06, 2025

Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK

Mar 06, 2025

Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St

Mar 06, 2025

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance

Mar 06, 2025

What is B. Riley’s Forecast for KYMR FY2025 Earnings? - Defense World

Mar 06, 2025

Mar 05, 2025

A Guide To The Risks Of Investing In Kymera Therapeutics Inc (KYMR) - Knox Daily

Mar 05, 2025

New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 05, 2025

Equities Analysts Offer Predictions for KYMR Q1 Earnings - Defense World

Mar 05, 2025

Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World

Mar 05, 2025

Mar 04, 2025

Kymera Therapeutics announces new performance-based stock plan By Investing.com - Investing.com Australia

Mar 04, 2025

Mar 03, 2025

Kymera Therapeutics COO sells $42,113 in stock By Investing.com - Investing.com South Africa

Mar 03, 2025

Kymera Therapeutics’ chief legal officer sells $68,239 in stock By Investing.com - Investing.com South Africa

Mar 03, 2025

Kymera Therapeutics CFO sells shares worth $214,219 By Investing.com - Investing.com South Africa

Mar 03, 2025

Kymera Therapeutics’ chief medical officer sells shares worth $174,785 By Investing.com - Investing.com Canada

Mar 03, 2025

Kymera Therapeutics CFO sells shares worth $214,219 - Investing.com India

Mar 03, 2025

Kymera Therapeutics’ chief medical officer sells shares worth $174,785 - Investing.com

Mar 03, 2025

Kymera Therapeutics COO sells $42,113 in stock - Investing.com

Mar 03, 2025

Kymera Therapeutics announces new performance-based stock plan - Investing.com India

Mar 03, 2025

Kymera Therapeutics Grants Performance Stock Units to Executives - TipRanks

Mar 03, 2025

Rhumbline Advisers Acquires 1,861 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 03, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St

Mar 01, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance

Mar 01, 2025

Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC Wainwright - MarketBeat

Mar 01, 2025

Feb 28, 2025

Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results - MarketBeat

Feb 28, 2025

Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Feb 28, 2025

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing Earnings - MarketBeat

Feb 28, 2025

(KYMR) Trading Signals - Stock Traders Daily

Feb 28, 2025

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus - TradingView

Feb 28, 2025